The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly

Clinical Endocrinology

Volumn 62, Issue 3, 2005, Pages 282-288

  Karavitaki, Niki ^a   Botusan, Ileana ^b   Radian, Serban ^b   Coculescu, Mihail ^b   Turner, Helen E ^a   Wass, John A H ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; LONG ACTING DRUG; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; GROWTH HORMONE BLOOD LEVEL; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TRANSSPHENOIDAL SURGERY;

ACROMEGALY; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PATIENT SELECTION; PEPTIDES, CYCLIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 15044348198     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2004.02191.x     Document Type: Article

References (29)

1. Colao, A., Ferone, D., Marzullo, P. & Lombardi, G. (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews, 25, 102-152.
2. Alexander, L., Appleton, D., Hall, R., Ross, W.M. & Wilkinson, R. (1980) Epidemiology of acromegaly in the Newcastle region. Clinical Endocrinology, 12, 71-79.
3. Orme, S.M., McNally, R.J.Q., Cartwright, R.A. & Belchetz, P.E. & the United Kingdom Acromegaly Study Group. (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. Journal of Clinical Endocrinology and Metabolism, 83, 2730-2734.
4. Bengtsson, B., Eden, S., Ernest, I., Oden, A. & Sjogren, B. (1988) Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Medica Scandinavica, 223, 327-335.
5. Rajasoorya, C., Holdaway, I.M., Wrightson, P., Scott, D.J. & Ibbertson, H.K. (1994) Determinants of clinical outcome and survival in acromegaly. Clinical Endocrinology, 41, 95-102.
6. Wright, A.D., Hill, D.M., Lowry, C. & Fraser, R.T. (1969) Mortality in acromegaly. Quarterly Journal of Medicine, 39, 1-16.
7. Nabarro, J.D.N. (1987) Acromegaly. Clinical Endocrinology, 26, 481-512.
8. Bates, A.S., Van't Hoff, W., Jones, J.M. & Clayton, R.N. (1993) An audit of outcome of treatment in acromegaly. Quarterly Journal of Medicine, 86, 293-299.
9. Lamberts, S.W., van der Lely, A.-J., de Herber, W.W. & Hofland, L.J. (1996) Octreotide. New England Journal of Medicine, 334, 246-254.
10. Shimon, I. & Melmed, S. (1997) Structure and function of somatostatin receptors in growth hormone control. Journal of Endocrinology, 155, S3-S6.
11. Freda, P.U. (2002) Somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism, 87, 3013-3018.
12. Bevan, J.S., Atkin, S.L., Atkinson, A.B., Bouloux, P.M., Hanna, F., Harris, P.E., James, R.A., McConnell, M., Roberts, G.A., Scanion, M.F., Stewart, P.M., Teasdale, E., Turner, H.E., Wass, J.A. & Wardlaw, J.M. (2002) Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. Journal of Clinical Endocrinology and Metabolism, 87, 4554-4563.
13. Newman, C.B., Melmed, S., Snyder, P.J., Young, W.F., Boyajy, L.D., Levy, R., Stewart, W.N., Klibanski, A., Molitch, M.E. & Gagel, R.F. (1995) Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients. A clinical research center study. Journal of Clinical Endocrinology and Metabolism, 80, 2768-2775.
14. Reubi, J.C. & Landolt, A.M. (1989) The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. Journal of Clinical Endocrinology and Metabolism, 68, 844-850.
15. Pieters, G.F.F.M., Smals, A.G.H. & Kloppenborg, P.WC. (1986) Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. New England Journal of Medicine, 314, 1390-1392.
16. Lamberts, S.W., Uitterlinden, P. & del Pozo, E. (1987) SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over 2 years. Journal of Clinical Endocrinology and Metabolism, 65, 703-710.
17. Lamberts, S.W., Uitterlinden, P., Schuijff, P.C. & Klijn, J.C. (1988) Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical 'cure'. Clinical Endocrinology, 29, 411-420.
18. Del Pozo, E., Neufeld, M., Schluter, K., Tortosa, F., Clarenbach, P., Bieder, E., Wendel, L., Nuesch, E., Marbach, P. & Cramer, H. ( 1986) Endocrine profile of a long-acting somatostatin derivative SMS 201-995. Study in normal volunteers following subcutaneous administration. Acta Endocrinologica, 111, 433-439.
19. Wass, J.A. (1990) Octreotide treatment of acromegaly. Hormone Research, 33, 1-5.
20. Plewe, G., Beyer, J., Krause, U., Neufeld, M. & del Pozo, E. (1984) Long-acting and selective suppression of growth hormone secretion by somatostatin SMS 201-995 in acromegaly. Lancet, 2, 782-784.
21. Colao, A., Ferone, D., Lastoria, S., Marzullo, P., Cerbone, G., Di Sarno, A., Longobardi, S., Merola, B., Salvatore, M. & Lombardi, G. (1996) Prediction of efficacy of octreotide therapy in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 81, 2356-2362.
22. Caron, P., Beckers, A., Cullen, D.R., Goth, M.I., Gutt, B., Lauberg, P., Pico, A.M., Valimaki, M. & Zgliczynski, W. (2002) Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. Journal of Clinical Endocrinology and Metabolism, 87, 99-104.
23. Heron, I., Thomas, F., Dero, M., Cancel, A., Ruiz, J.M., Schatz, B. & Kuhn, J.M. (1993) Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 76, 721-727.
24. Stewart, P.M., Kane, K.F., Stewart, S.E., Lacranjan, I. & Sheppart, M.C. (1995) Depot long-acting somatostatin analog (Sandostatin LAR) is an effective treatment for acromegaly. Journal of Clinical Endocrinology and Metabolism, 80, 3267-3272.
25. Serri, O., Beauregard, C. & Hardy, J. (2004) Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 89, 658-661.
26. Swearingen, B., Barker, G., Katznelson, L., Biller, B.M., Grinspoon, S., Klibanski, A., Moayeri, N., Black, P.M. & Zervas, N.T. (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism, 83, 3419-3426.
27. Holdaway, I.M., Rajasoorya, R.C. & Gamble, G.D. (2004) Factors influencing mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism, 89, 667-674.
28. Ayuk, J., Clayton, R.N., Holder, G., Sheppard, M.C., Stewart, P.M. & Bates, A.S. (2004) Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 89, 1613-1617.
29. Cozzi, R., Attanasio, R., Montini, M., Pagani, G., Lasio, G., Lodrini, S., Barausse, M., Albizzi, M., Dallabonzana, D. & Pedroncelli, A.M. (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? Journal of Clinical Endocrinology and Metabolism, 88, 3090-3098.